WO1987001590A1 - Composition destinee a etre utilisee dans le traitement de l'obesite - Google Patents

Composition destinee a etre utilisee dans le traitement de l'obesite Download PDF

Info

Publication number
WO1987001590A1
WO1987001590A1 PCT/GB1986/000560 GB8600560W WO8701590A1 WO 1987001590 A1 WO1987001590 A1 WO 1987001590A1 GB 8600560 W GB8600560 W GB 8600560W WO 8701590 A1 WO8701590 A1 WO 8701590A1
Authority
WO
WIPO (PCT)
Prior art keywords
tryptophan
diet
amount
daily
grams
Prior art date
Application number
PCT/GB1986/000560
Other languages
English (en)
Inventor
Stephen Neil Kreitzman
Original Assignee
Stephen Neil Kreitzman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stephen Neil Kreitzman filed Critical Stephen Neil Kreitzman
Publication of WO1987001590A1 publication Critical patent/WO1987001590A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the treatment of obesity and, in particular, to an agent for the control of appetite, when used together with a low protein diet and compositions containing the same.
  • the compound L-tryptophan is known as an essential aminoacid and, as such, is known as a compound required for human nutrition.
  • L-tryptophan is sold in the U.K. in tablet or capsule form for use as a nutritional supplement.
  • L-tryptophan is presently marketed in the U.K. either alone or in combination with pyridoxine hydrochloride (vitamin B6) and ascorbic .acid as an agent for the treatment of disorders of the central nervous system, in particular as an anti- depressant, a sleep-inducer and/or a mood calmer.
  • Trptophan has not been reported to have consistent effects on hunger per se, and thus probably did not exert its effect by simply suppressing appetite among the three responders. Weinberger et al [supra] ....found no reduction in food intake among food-deprived rats during the tw-o hours after treatment with sufficient tryptophan (50 or 100 mg/kg) to raise brain tryptophan levels. Latham and Blundell (1979) observed a slight decrease in food intake among rats feeding freely on a single test diet, and no change in total daily food intake among food-deprived animals. The decrease in food intake resulted from a decrease in meal size and an increase in the between-meal interval.”
  • tryptophan reduced the magnitude of the first enormous meal normally consumed by rats when allowed access to food
  • tryptophan may have some small effect on food intake, there is nothing in that prior art ' to suggest either that tryptophan can have a pronounced effect on food intake and/or as to the manner in which the effect of tryptophan can be made consistent.
  • a composition for suppressing appetite for calories as carbohydrates may be based on tryptophan.
  • Such a composition is broadly defined as one which, when administered to an animal (prior to consuming food), decreases appetite for calories as carbohydrates which consists essentially of an amount of tryptophan effective to increase brain serotonin levels and a carbohydrate in an amount effective to cause insulin to be released in the animal.
  • the weight ratio of the tryptophan to the ⁇ arbohydrate(s) is between about 0.05 and about 5.0, more usually between about 0.20 and about 2.0.
  • the compositions of that invention are administered in an amount sufficient to effect increase in brain serotonin levels while not being administered in such large amounts as seriously to reduce the brain levels of other neurotransmitters needed for normal functioning such as dopamine, norepinephrine, acetylcholine, or the non-essential amino acids.
  • compositions of that invention are administered in an amount of between about 10 mg/kg and about 100 mg/kg of tryptophan, and 10 mg/kg and 300 mg/kg of carbohydrate, more usually between 20 mg/kg and about 50 mg/kg of tryptophan, and 30 mg/kg and 150 mg/kg of carbohydrate.
  • Typical unit dosage forms useful for oral administration are said to range between about 0.5 grams and about 15 grams, and more usually between about 1 gram and about 10 grams.
  • the earlier invention provides a method and composition for suppressing appetite for calories (as carbohydrates) while elevating the percent of total calories that is consumed as protein.
  • the invention is based upon the discovery that a combination of tryptophan and a carbohydrate (which causes insulin secretion) selectively suppresses the appetite for calories (as carbohydrates).
  • the mixture of tryptophan and said carbohydrate can be administered alone, in admixture with one or more amino acids normally found in the blood plasma, or with caffeine or another mild stimulant, to override the mixture's natural sedating effects. It is said to be believed that the compositions function by mechanisms which involve the enhancement of brain serotonin synthesis, serotonin being a neurotransmitter involved in the control of appetite.
  • L- tryptophan can be used as a powerful agent in the control of appetite provided it is administered in conjunction with an essentially nutritionally complete diet which has a content of protein, typically as calculated on a daily basis, below that normally taken by the subj ect under treatment.
  • the present invention provides, in its broadest aspect, L-tryptophan for use in the treatment of obesity, especially in man, as an agent for the control of appetite when used in conjunction with a protein-restricted diet.
  • the invention is for L-tryptophan when put up for use as an agent for the control of appetite as part of a protein-restricted dietary regimen, in particular, L-tryptophan in unit dosage form when put up for that use.
  • protein-restricted diet means a diet for any one particular individual which is reduced in its content of proteinaceous material to below that individual's normal average daily intake of said material.
  • a diet will generally comprise significantly less than about 250 grams per day, preferably 100 grams per day or ' less, of proteinaceous material.
  • the invention is concerned with the use of L-tryptophan in conjunction with a diet which while it is restricted in protein, and while it of necessity must be restricted in calories (if successful weight reduction is to be obtained), nevertheless is otherwise an essentially complete diet in a nutritional sense. That is to say the diet on a long term basis should be able to supply the patient's minimum nutritional requirements of minerals, vitamins, protein, carbohydrate and/or fat to maintain health.
  • the L- tryptophan may be put up for use with either a solid carrier or a liquid carrier, provided it is a low- protein carrier.
  • the carrier may be an item of confectionary such as a chocolate, candy or "nutty" crunch bar, or say a chewing gum, or a carrier based on cereal or vegetable material such as a pasta, a crisp or chip.
  • a liquid carrier may be a beverage such as a beer or the like.
  • compositions for use in the treatment of obesity which composition comprises L-tryptophan and a protein-restricted diet composition as carrier, the amount of L-tryptophan in the composition being such as to provide at least about 0.5 grams of L-tryptophan per daily amount of diet.
  • a composition for use in the treatment of obesity in accordance with the invention is a composition which comprises L-tryptophan and a protein- restricted formula diet as a carrier therefor, the amount of L-tryptophan in the composition being such as to provide at least about 0.5 grams of L-tryptophan per daily amount of diet, and said diet comprising on a daily amount basis less than about 100 grams of proteinaceous material, and an energy level of no more than about 1000 Kcals.
  • a pack for use in the treatment of obesity which pack comprises L- tryptophan put up for use as an agent for the control of appetite, together with instructions for using L- tryptophan in the treatment of obesity in conjunction with a protein-restricted diet.
  • the instructions typically may recommend the use of from about 0.5 to about 12 grams, preferably about 0.5 to about 10 grams per day of L-tryptophan in conjunction with a daily diet containing no more than about 100 grams per day of other proteinaceous material.
  • the invention provides a method for the treatment of obesity, especially in man f> which method comprises giving to an overweight patient a daily diet in which the amount of proteinaceous material is restricted below the patient's normal average daily intake of protein, together with a daily dose of at least about 0.5 grams, typically from about 0.5 to about 12 grams, and preferably from about 0.5 to about 10 grams, of L-tryptophan as appetite suppressant.
  • the daily dose of L-tryptophan can be administered in a plurality of amounts throughout the day.
  • the daily dose of L-tryptophan may be divided into three one-third amounts each to be consumed with the diet at the three daily diet meals.
  • the sub-division may be by any desired factor provided overall the necessary daily dose is consumed.
  • the patient's daily diet should preferably also be restricted to a daily energy level of no more than about 1000 Kcals, in order to achieve a reasonably efficient rate of weight loss. More preferably, the amount of prot ⁇ inaceous material in the patient's daily diet should be at least about 15 grams per day, with an amount of proteinaceous material in the patient's daily diet of from about 15 to about 55 grams per day being especially preferred. Most preferably, however, the amount of proteinaceous material in the patient's daily diet should be from about 30 to about 45 grams per day.
  • the patient may be given a daily fresh food diet in which the amount of proteinaceous material is restricted.
  • the patient is given a daily formula diet in which the amount of proteinaceous material is restricted, both because the amount of proteinaceous material can thereby be controlled more accurately, and because the amounts of essential minerals and the amounts of vitamins given per day can be kept relatively independent of the daily energy level of the diet.
  • the daily energy level can be kept below that at which with a fresh food diet the subject could not obtain all of the necessary minerals and/or vitamins in their recommended daily amounts.
  • a formula diet in the case where a formula diet is employed it may comprise a diet in accordance with that disclosed in British Specification No. 1,356,730 (as well as U.S. Specifications Nos. 4,009,265 and 4,298,601), the dislosures of each of which are incorporated herein by way of reference.
  • Such a formula diet is defined as one which comprises: a) all the minerals required by man; b) proteinaceous material consisting of: i ) a mixture of monomeri ⁇ L-aminoa ⁇ ids , and/or ii ) natural proteins , and/or iii ) natural proteins reinforced with at least one monomeric L-aminoacid; and c) digestible carbohydrate; such that the smallest amount of the dietary formulation containing at least the minimum daily requirements of each of the minerals required by man also contains: A) at least about 15 grams of the proteinaceous material which must include at least the minimum daily requirements for man of all the essential L- aminoacids required by man; and B) from about 15 to about 75 grams of the digestible carbohydrate and such that the total calorific value of the said smallest amount of the dietary formulation is in the range of from about 160 Kcals to about 600 Kcals.
  • the various features of that earlier invention may be used as required or desired or preferred.
  • the diet will be one containing minerals (more preferably at least essentially all required minerals), vitamins (more preferably at least essentially all required vitamins) and a small amount of fat in accordance with the preferred aspects of the earlier disclosure.
  • the necessary appetite-controlling effect of L-tryptophan can be obtained using daily amounts of the "compound of from about 0.5 grams and upwards, nevertheless the preferred upper limit per day is about 10 or 12 grams and, more preferably the patient should be given a daily dose of from about 3 to about 5 or 6 grams of L-tryptophan as appetite suppressant. Furthermore, the daily dose of L-tryptophan as given should be in addition to the patient's normal requirement of L-tryptophan as an essential aminoacid, which is usually, about 0.25 grams in an adult male.
  • L-tryptophan together with that commercially-available diet in accordance with British Specification No. 1,356,730 available inter alia in the U.K. and the U.S.A.
  • composition in accordance with the invention as defined above generally will contain an amount of L-tryptophan which reflects the above parameters and/or permits them to be followed in carrying out the method of the invention.
  • L-tryptophan can be regarded as a powerful appetite suppressant per se within the context of any protein-restricted diet, it provides a significant and particularly useful advantage when used in conjunction with a very low calorie formula diet. With such a diet the first one to three days are always difficult, and similar difficulties can arise if the diet is broken at four weeks, as is often recommended. In some cases it may seem almost impossible to get back on such a diet after it is broken.
  • L-tryptophan solves those problems.
  • L-tryptophan even permits the dieter to cheat (preferably only on special occasions) provided cheating is carried out on the basis of consuming a treat which is low in protein. Since most overweight people like to cheat with treats which are low in protein, L-tryptophan is an ideal adjunct to the use of a very low calorie formula diet such as "The Cambridge Diet", with isolated bouts of cheating.
  • the use of L-tryptophan introduces a degree of flexibility to dieting at about or below the 1000 kcal level, with protein restriction, which is hitherto unknown.
  • the dieter in a very low calorie diet situation need no longer rely entirely on the mild ketosis effect to suppress hunger and need no longer fear the consequences of breaking the diet even for say one meal.
  • the use of L-tryptophan can assist the dieter and the dietician in combining the use of very low calorie dieting regimens with other approaches to provide a variety and flexibility of approach which minimise the dieter's discomfort during the dieting period.
  • Such diets are nutritionally complete, they are protein restricted and, furthermore, they are carbohydrate restricted to the extent that the daily amount of carbohydrate given or supplied is a protein sparing amount of carbohydrate, generally from about 15 to about 75 grams per day. More preferably, as indicated, in the specific Examples below, the amount of carbohydrate should be at least about 30 grams per day or more and up to about 70 grams per day.
  • use of L- tryptophan in the present invention is preferably a use within the context of a diet which of itself lowers blood sugar and not within a context which deliberately causes insulin to be released by raising blood sugar.
  • L-tryptophan at a preferred total level of over 3 grams per day, i.e. a preferred level at 3 grams plus the 0.25 gram or other amount supplied by the carrier, i.e. the diet per se.
  • L-tryptophan over an extended period of time for the treatment of those who are signi icantly overweight.
  • the invention includes tryptophan for the manufacture of an agent for the control of appetite when used in conjunction with a protein-restricted diet.
  • Example 1 A composition in accordance with the invention is formulated as follows:
  • composition on a daily basis provides a daily energy level of about 330 kcals.
  • Example 2 A composition in accordance with the invention is formulated as follows:
  • composition on a daily basis provides a daily energy level of about 330 kcals.
  • Example 3 A composition in accordance with the invention is formulated as follows:
  • Example 4 A composition in accordance with the invention is formulated as follows:
  • Vitamins and minerals Vitamin A 1.0 mg Vitamin B-» 1.5 mg Vitamin B2 1.7 mg Niacin 19.0 mg Vitamin Bg 2.2 mg Pantothenic Acid 7.0 mg Biotin 200.0 meg
  • composition on a daily basis provides a daily energy level of about 330 kcals.
  • composition in accordance with the invention is formulated as follows
  • composition on a daily basis of consuming three servings amounting to a total of 100 grams per day provides a daily energy level of about 290 kcals.
  • a pack in accordance with the .invention comprises a seven-day supply of a Cambridge Diet product of Cambridge Nutrition Limited, having a formulation as set out in Example 4 above, except for the 3 grams of L- tryptophan, together with 42 tablets or capsules containing 500 mg of L-tryptophan.
  • a Cambridge Diet product of Cambridge Nutrition Limited having a formulation as set out in Example 4 above, except for the 3 grams of L- tryptophan, together with 42 tablets or capsules containing 500 mg of L-tryptophan.
  • Diet is taken three times a day as directed, e.g. at about 33 grams per serving, together with two 500 mg doses of L-tryptophan to provide a daily energy level of about 330 kcals, a daily amount of protein of about 34 grams and a daily amount of L-tryptophan of about 3 grams.
  • Example 7 Each of the above Examples is repeated except that the level of L-tryptophan is set at 5 grams per day.
  • Example 8 Each of the above Examples is repeated except that the level of L-tryptophan is set at 6 grams per day.
  • the daily amount of protein can be above or below the exemplified amounts provided the protein is preferably within the range of from about 15 to about 100 grams per day.
  • the amount of L-tryptophan consumed per day preferably may be.any amount within the range of from about 0.5 grams to about 10 or about 12 grams, and the daily energy level can be varied" widely preferably within the range of from about 160 kcals up to about 1000 kcals.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon la présente invention, se rapportant au traitement de l'obésité notamment chez l'homme, un patient obèse est soumis à un régime journalier dans lequel la quantité de substances protéiques est inférieure à la quantité protéique moyenne journalière absorbée par le patient, en combinaison avec une dose journalière d'au moins 0,5 grammes environ de L-tryptophane utilisé comme agent suppresseur de l'appétit. La composition ci-décrite, destinée à être utilisée dans le traitement de l'obésité, comprend du L-tryptophane et une composition diététique à teneur réduite en protéines utilisée comme support, la quantité de L-tryptophane dans la composition étant égale à au moins 0,5 grammes environ de L-tryptophane par dose journalière. De préférence, le support est une formulation diététique à teneur réduite en protéines, dont une dose journalière comprend moins de 100 grammes environ de substances protéiques et un niveau énergétique ne dépassant pas 1000 Kcals environ.
PCT/GB1986/000560 1985-09-20 1986-09-19 Composition destinee a etre utilisee dans le traitement de l'obesite WO1987001590A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8523338 1985-09-20
GB858523338A GB8523338D0 (en) 1985-09-20 1985-09-20 Treatment of obesity

Publications (1)

Publication Number Publication Date
WO1987001590A1 true WO1987001590A1 (fr) 1987-03-26

Family

ID=10585524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1986/000560 WO1987001590A1 (fr) 1985-09-20 1986-09-19 Composition destinee a etre utilisee dans le traitement de l'obesite

Country Status (3)

Country Link
EP (1) EP0238533A1 (fr)
GB (2) GB8523338D0 (fr)
WO (1) WO1987001590A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2648044A1 (fr) * 1989-06-07 1990-12-14 Norchim Composition pharmaceutique liquide presentant une activite anorexigene
FR2657013A1 (fr) * 1990-01-18 1991-07-19 Medgenix Group Sa Composition dietetique a base de polypeptides et acides amines.
GB2292522A (en) * 1994-08-22 1996-02-28 Gitta Carmen Conway Multi-vitamin preparation for treatment of the immune system
ES2087027A1 (es) * 1994-08-03 1996-07-01 Univ Illes Balears Suplementos nutricionales termogeneticos, alimentos que los contienen y aplicaciones.
EP0951842A2 (fr) * 1999-01-20 1999-10-27 N.V. Nutricia Aliment pour bébé
FR2777751A1 (fr) * 1998-04-23 1999-10-29 Pro Dietic Rdp Complement proteique, composition alimentaire le contenant, leur procede de preparation et leur utilisation.
WO1999055174A1 (fr) * 1998-04-23 1999-11-04 Pro Dietic Rdp (S.A.R.L.) Complement proteique, composition alimentaire le contenant, leur procede de preparation et leur utilisation
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
EP1071326A1 (fr) * 1998-04-15 2001-01-31 Nutriceutical Technology Corporation Methode pour reguler l'appetit et le metabolisme
WO2004069265A1 (fr) * 2003-02-07 2004-08-19 Campina B.V. Utilisation de peptides riches en tryptophane
CN109803546A (zh) * 2016-09-29 2019-05-24 雀巢产品技术援助有限公司 减少食物渴望、促进体重减轻和/或治疗超重或肥胖的方法
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153548B8 (fr) 2000-05-12 2007-06-27 NattoPharma ASA Produit alimentaire contenant de la vitamine k2
GB0220182D0 (en) * 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
ITTO20070391A1 (it) * 2007-06-05 2008-12-06 Medestea Res & Production S P Composizione di integratore alimentare,farmaco o dispositivo medicale e suo impiego per sopprimere l'appetito, migliorare tono ed umore, con attivita antidepressiva naturale e con effetto antiastenico

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1289096A (fr) * 1968-10-03 1972-09-13
US3809752A (en) * 1971-03-24 1974-05-07 W Fishman Anti-obesity process
US4042687A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of treating obesity by the oral administration of a predigested protein composition
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
EP0147699A2 (fr) * 1984-01-04 1985-07-10 Societe Des Produits Nestle S.A. Produit alimentaire efficace dans le traitement de la lépre

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3150044A (en) * 1962-04-18 1964-09-22 Sam I Stein Treatment and composition for high blood pressure and palpitation
DE2305209A1 (de) * 1972-02-14 1973-08-23 Hoffmann La Roche Pharmazeutisches praeparat
US4298601A (en) * 1972-03-06 1981-11-03 Technutra, S.A. Method and formulations for the treatment of obesity
GB1356370A (en) * 1972-03-06 1974-06-12 Howard A N Methods and formulations for the treatment of obesity
US4210637A (en) * 1978-07-31 1980-07-01 Massachusetts Institute Of Technology Composition and method for suppressing appetite for calories as carbohydrates
US4377595A (en) * 1979-08-13 1983-03-22 Massachusetts Institute Of Technology Process for reducing depression
DK198583A (da) * 1982-05-20 1983-11-21 Showa Denko Kk Svinefoder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1289096A (fr) * 1968-10-03 1972-09-13
US3809752A (en) * 1971-03-24 1974-05-07 W Fishman Anti-obesity process
US4042687A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of treating obesity by the oral administration of a predigested protein composition
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
EP0147699A2 (fr) * 1984-01-04 1985-07-10 Societe Des Produits Nestle S.A. Produit alimentaire efficace dans le traitement de la lépre

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2648044A1 (fr) * 1989-06-07 1990-12-14 Norchim Composition pharmaceutique liquide presentant une activite anorexigene
FR2657013A1 (fr) * 1990-01-18 1991-07-19 Medgenix Group Sa Composition dietetique a base de polypeptides et acides amines.
WO1991010441A1 (fr) * 1990-01-18 1991-07-25 Medgenix Group S.A. Composition a base de polypeptides et acides amines
ES2087027A1 (es) * 1994-08-03 1996-07-01 Univ Illes Balears Suplementos nutricionales termogeneticos, alimentos que los contienen y aplicaciones.
GB2292522A (en) * 1994-08-22 1996-02-28 Gitta Carmen Conway Multi-vitamin preparation for treatment of the immune system
GB2292522B (en) * 1994-08-22 1999-01-27 Gitta Carmen Conway A nutritional preparation for the human or animal immune system
EP1071326A1 (fr) * 1998-04-15 2001-01-31 Nutriceutical Technology Corporation Methode pour reguler l'appetit et le metabolisme
EP1071326A4 (fr) * 1998-04-15 2003-03-05 Nutriceutical Technology Corp Methode pour reguler l'appetit et le metabolisme
KR20010052257A (ko) * 1998-04-15 2001-06-25 뉴트리슈티컬 테크놀러지 코아포레이션 식욕과 신진대사를 조절하는 방법
FR2777751A1 (fr) * 1998-04-23 1999-10-29 Pro Dietic Rdp Complement proteique, composition alimentaire le contenant, leur procede de preparation et leur utilisation.
WO1999055174A1 (fr) * 1998-04-23 1999-11-04 Pro Dietic Rdp (S.A.R.L.) Complement proteique, composition alimentaire le contenant, leur procede de preparation et leur utilisation
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
WO2000042868A1 (fr) * 1999-01-20 2000-07-27 N.V. Nutricia Formule pour enfants en bas âge
EP0951842A3 (fr) * 1999-01-20 1999-12-22 N.V. Nutricia Aliment pour bébé
EP0951842A2 (fr) * 1999-01-20 1999-10-27 N.V. Nutricia Aliment pour bébé
US6613367B1 (en) 1999-01-20 2003-09-02 N.V. Nutricia Infant formula
US8124585B2 (en) * 1999-01-20 2012-02-28 N.V. Nutricia Composition for relieving discomfort
US8450347B2 (en) 1999-01-20 2013-05-28 N.V. Nutricia Composition for relieving discomfort
WO2004069265A1 (fr) * 2003-02-07 2004-08-19 Campina B.V. Utilisation de peptides riches en tryptophane
US7582601B2 (en) 2003-02-07 2009-09-01 Campina B.V. Use of tryptophan rich peptides
CN109803546A (zh) * 2016-09-29 2019-05-24 雀巢产品技术援助有限公司 减少食物渴望、促进体重减轻和/或治疗超重或肥胖的方法
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法

Also Published As

Publication number Publication date
GB2180747A (en) 1987-04-08
GB8622618D0 (en) 1986-10-22
EP0238533A1 (fr) 1987-09-30
GB8523338D0 (en) 1985-10-23

Similar Documents

Publication Publication Date Title
CA2627837C (fr) Compositions pharmaceutiques permettant d'attenuer les sensations de malaise
EP0482715B1 (fr) Composition nutritionnelle
Bensaı̈d et al. Protein is more potent than carbohydrate for reducing appetite in rats
EP0007691B1 (fr) Compositions à utiliser pour diminuer l'appétit de calories d'hydrates de carbone
Lagua et al. Nutrition and diet therapy reference dictionary
WO1987001590A1 (fr) Composition destinee a etre utilisee dans le traitement de l'obesite
US7976879B2 (en) Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions
CA2284664A1 (fr) Supplements nutritionnels ameliorant le metabolisme du glucose
AU3666497A (en) Appetite suppression
WO1997014422A1 (fr) Composition a complement vitaminique multiple
Kumar et al. Impact of acute corticosterone administration on feeding and macronutrient self-selection patterns
US6605646B2 (en) Vitamin supplement composition
Baker et al. Vitamin and mineral supplementation in patients with diabetes mellitus
EP1410722A1 (fr) Kit de perte de poids et méthode pour perdre du poids
US20140024674A1 (en) Trpm5 inhibitors support body weight reduction without reducing food intake
Holliday et al. Nutritional management of chronic renal disease
WO2019130167A1 (fr) Composition destinée à être utilisée dans le traitement de malabsorption suite à une chirurgie bariatrique
RU2335927C2 (ru) Обогащенные лейцином питательные композиции
Giampapa Every man takes the limits of his own field of vision for the limits of the world.
Giampapa Diet and Aging
Manjunath Shenoy et al. Nutritional Dermatoses
WO2003088953A2 (fr) Regime alimentaire multiphasique
Lagua T. Abbreviation for temperature. T3• Abbreviation for triiodothyronine, a thyroid hormone. See Thyroid gland. T 4'Abbreviation for tetraiodothyronine
Hashim Obesity, Drugs and Formula Diets
Berdanier Nutrition in the Later Years

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986905379

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986905379

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986905379

Country of ref document: EP